You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

25 Results
Drug
Other Name(s): Camptosar®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2025
Drug
Other Name(s): Imbruvica®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2026
Drug
Other Name(s): Ninlaro™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Regimen
Cancer Type:
Sarcoma, 
Ewing's, 
Soft Tissue
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Drugs Used:
etoposide,
ifosfamide,
mesna,
vinCRIStine,
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2019
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Cetuximab with Irinotecan - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
cetuximab,
irinotecan
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
irinotecan
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For relapsed and refractory mantle cell lymphoma, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iBRUtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iBRUtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Drugs Used:
ifosfamide,
mesna,
CARBOplatin,
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
idelalisib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2019
Regimen
Cancer Type:
Sarcoma, 
Ewing's
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
irinotecan,
temozolomide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For the treatment of patients with relapsed or refractory Waldenstrӧm Macroglobulinemia, as monotherapy, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iBRUtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2026

Pages